Related and Nonrelated Parties [Axis]
Related Party [Member]
Class of Stock [Axis]
Series C 9% Convertible Preferred Stock [Member]
Series A Preferred Stock [Member]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Series E Preferred Stock [Member]
Series F Preferred Stock [Member]
Product and Service [Axis]
Service [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Business Acquisition [Axis]
Viral Clear[Member]
Investment, Name [Axis]
BioSig AI Sciences, Inc. [Member]
Statistical Measurement [Axis]
Minimum [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Concentration Risk Benchmark [Axis]
Revenue Benchmark [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Customer [Axis]
Customer One [Member]
Accounts Receivable [Member]
Customer Two [Member]
Customer Three [Member]
Maximum [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Patents [Member]
ViralClear Pharmaceuticals, Inc. [Member]
BioSig AI Sciences, Inc. [Member]
Ownership [Axis]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Warrant [Member]
Restricted Stock [Member]
Long-Lived Tangible Asset [Axis]
Computer Equipment [Member]
Furniture and Fixtures [Member]
Testing/Demo equipment [Member]
Leasehold Improvements [Member]
Sale Leaseback Transaction, Description [Axis]
Contract Assets Current [Member]
Contract Assets Noncurrent [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Title and Position [Axis]
Consultant [Member]
Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Purchase Agreement [Member]
Legal Entity [Axis]
H. C Wainwright And Co L L C [Member]
Sales Agreement [Member]
Market Offering Agreement [Member]
Plan Name [Axis]
2023 Long-Term Incentive Plan [Member]
Key Consultant [Member]
2019 Long-Term Incentive Plan [Member]
Exercise Price Range [Axis]
Options Under 9.99 [Member]
Options 10.00 To 19.99 [Member]
Options 20.00 To 49.99 [Member]
Options 50.00 To 69.99 [Member]
Warrants At 0.3000 [Member]
Warrants At 0.9547 [Member]
Warrants At 1.7800 [Member]
Warrants At 2.3875 [Member]
Warrants At 3.3640 [Member]
Warrants At 3.5730 [Member]
Warrants At 4.0660 [Member]
Warrants At 4.4550 [Member]
Warrants At 4.4660 [Member]
Warrants At 4.6626 [Member]
Warrants At 4.9252 [Member]
Warrants At 4.9290 [Member]
Warrants At 5.1358 [Member]
Warrants At 7.1810 [Member]
Warrants At 7.5020 [Member]
Warrants At 7.9630 [Member]
Warrants At 9.0000 [Member]
Warrants At 9.5960 [Member]
Warrants At 10.0992 [Member]
Warrants At 10.2600 [Member]
Warrants At 10.4678 [Member]
Warrants At 11.3000 [Member]
Warrants At 13.2800 [Member]
Warrants At 14.0000 [Member]
Warrants At 48.0000 [Member]
Warrants At 61.6000 [Member]
Range One [Member]
Range Two [Member]
Consolidated Entities [Axis]
2017 Know-How License Agreement [Member]
E P Software Agreement [Member]
Tools Agreement [Member]
Viral Clear Patent Agreement [Member]
Trek Therapeutics [Member]
First Country [Member]
Second Country [Member]
Subscription Agreement [Member]
Settlement Agreement [Member]
Segments [Axis]
Corporate Segment [Member]
Interim Chief Financial Officer [Member]
Mr. Groenewald [Member]
Chief Executive Officer [Member]
Mr Amato [Member]
Consultants [Member]
Endicott Management Partners LLC. [Member]
Streamex Exchange Corporation [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash
Accounts receivable
Net investment in leases, short term
Prepaid expenses and vendor deposits
Total current assets
Property and equipment, net
Right-to-use assets, net
Other assets:
Net investment in leases, long term
Patents, net
Other assets
Total assets
LIABILITIES AND EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued expenses, including $0 and $19 to related parties as of March 31, 2025 and December 31, 2024, respectively
Dividends payable
Lease liability, short term
Total current liabilities
Total liabilities
Commitments and contingencies (Note 11)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of March 31, 2025 and December 31, 2024
Equity (Deficit)
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of March 31, 2025 and December 31, 2024 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 24,248,315 and 17,239,096 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively
Additional paid-in-capital
Accumulated deficit
Total stockholders’ equity (deficit) attributable to BioSig Technologies, Inc.
Non-controlling interest
Total equity (deficit)
Total liabilities and equity (deficit)
Statement [Table]
Statement [Line Items]
Accounts payable and accrued expenses, related parties
Temporary equity, par value
Temporary equity, stated value
Temporary equity, shares authorized
Temporary equity, shares issued
Temporary equity, shares outstanding
Temporary equity, liquidation preference
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenue:
Total revenue
Operating expenses:
Research and development
General and administrative
Impairment of long term assets
Depreciation and amortization
Total operating expenses
Loss from operations
Other income (expense)
Interest expense, net
Gain on settlement and extinguishment of accounts payable
Other income (expense), net
Total other income (expense), net
Loss before income taxes
Income taxes (benefit)
Net loss
Non-controlling interest
Net loss attributable to BioSig Technologies, Inc.
Preferred stock dividend
Preferred stock deemed dividend
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
Net loss per common share, basic
Net loss per common share, diluted
Weighted average number of common shares outstanding, basic
Weighted average number of common shares outstanding, diluted
Balance
Balance, shares
Common stock issued for services
Common stock issued for services, shares
Exercise of warrants
Exercise of warrants, shares
Stock based compensation
Stock based compensation, shares
Sale of common stock under-at-the market offering, net of transaction costs
Sale of common stock under-at-the market offering, net of transaction costs, shares
Sale of common stock and warrants
Sale of common stock and warrants, shares
Stock issued as extinguishment of debt
Stock issued as extinguishment of debt, shares
Preferred stock dividend
Net income (loss)
Sale of common stock and warrants
Sale of common stock and warrants, shares
Accretion of deemed preferred stock dividend
Deemed preferred stock dividend
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Non-cash lease expense
Impairment of long-term assets
Gain on settlement and extinguishment of accounts payable
Equity based compensation
Changes in operating assets and liabilities:
Accounts receivable
Lease receivables
Prepaid expenses and other
Employee advances
Customer deposits
Accounts payable and accrued expenses
Operating lease liabilities
Net cash used in operating activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of related party note payable
Proceeds from sale of common stock and warrants, net of issuance costs
Proceeds from sale of common stock under at-the-market offerings, net of issuance costs
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash, beginning of the period
Cash, end of the period
Supplemental disclosures of cash flow information:
Cash paid during the period for interest
Cash paid during the period for income taxes
Noncash investing and financing activities:
Common stock issued in settlement of debt
Dividend payable on preferred stock charged to additional paid in capital
Series C convertible preferred stock deemed dividend
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT
Right To Use Assets And Lease Liability
RIGHT TO USE ASSETS AND LEASE LIABILITY
Lease Receivables
LEASE RECEIVABLES
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Equity [Abstract]
STOCKHOLDER EQUITY
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS
Noncontrolling Interest [Abstract]
NON-CONTROLLING INTEREST
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Segment Reporting [Abstract]
SEGMENT REPORTING
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Principals of consolidation
Use of Estimates
Revenue Recognition
Allowance for Credit losses
Concentrations of Credit Risk
Fair Value of Financial Instruments
Prepaid Expenses and Vendor Deposits
Leases (lessee)
Leases (lessor)
Property and Equipment
Impairment of Long-lived Assets
Research and Development Costs
Net Income (loss) Per Common Share
Stock Based Compensation
Patents, Net
Segment Information
Non-controlling Interest
Warrants
Recent Accounting Pronouncements
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
SCHEDULE OF PROPERTY AND EQUIPMENT
SCHEDULE OF RIGHT TO USE ASSETS
SCHEDULE OF LEASE LIABILITY
SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS
SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE
SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS
SCHEDULE OF STOCK OPTION ACTIVITY
SCHEDULE OF INFORMATION RELATED TO WARRANTS
SCHEDULE OF WARRANT ACTIVITY
SCHEDULE OF RESTRICTED STOCK ACTIVITY
SCHEDULE OF NON-CONTROLLING INTEREST
SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST
SCHEDULE OF SEGMENT REPORTING
Sale of stock, shares
Sale of stock, value
Shares issued for acquisition
Ownership percentage
Equity method investment, ownership percentage
Auction Market Preferred Securities, Stock Series, Liquidation Value
Stockholders' Equity, Other
Share price
Working capital deficit
Net cash in operating activities
Totals
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Concentration risk, percentage
Allowance for doubtful accounts
Bad debt expenses
FDIC limits
Estimated useful lives
Finite-Lived Intangible Asset, Useful Life
Amortization
Non-controlling interest rate
Subsidiary, ownership percentage, noncontrolling owner
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Total
Less accumulated depreciation
Property and equipment, net
Impairment of long lived assets
Depreciation expenses
Schedule Of Right To Use Assets
Right to use asset
Less accumulated amortization
Right to use assets, net
Schedule Of Lease Liability
Total lease liability
Less: short term portion
Long term portion
Year ended December 31, 2025
Total
Less: Present value discount
Lease liability
Operating lease, expense
Operating lease, description
Operating lease expense
Sale Leaseback Transaction [Table]
Sale Leaseback Transaction [Line Items]
Balance
Recognized in Revenue
Invoiced to Customer
Interest Earned
Unguaranteed Residual Assets
Balance
Recognized in Revenue
Unguaranteed Residual Assets
Operating leases, rent expense
Operating lease, term of contract
Operating lease, renewal term
Lessor sales type lease discount rate
Accrued accounting and legal
Accrued reimbursements and travel
Accrued consulting
Accrued research and development expenses
Accrued marketing
Accrued office and other
Accrued settlement expenses
Accrued payroll
Accounts payable and accrued expenses
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Preferred stock, par or stated value per share (in dollars per share)
Preferred stock, shares issued
Dividends payable
Common Stock, Shares Authorized
Common Stock, Shares, Outstanding
Reverse stock split
Stock Issued During Period, Shares, Issued for Services
Stock Issued During Period, Value, Issued for Services
Number of shares issued
Number of shares exercised
Number of shares exercised
Sale of Stock, Number of Shares Issued in Transaction
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Purchase price of warrants
Exercise price, warrants
Sale of stock, consideration received on transaction
Stock issued during period, shares, new issues
Shares issued, price per share
Class of warrant or rights granted
Proceeds from issuance or sale of equity
Stock issued during period, shares, new issues
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price
Number of Options Outstanding
Number of Options Outstanding Weighted Average Remaining Life
Number of Options Outstanding Options Exercisable
Options Outstanding, Exercise Price
Outstanding shares
Weighted Average Exercise Price Outstanding
Weighted-Average Remaining Contractual Term
Outstanding Aggregate Intrinsic Value
Issued
Weighted Average Exercise Price Issued
Forfeited/expired
Weighted Average Exercise Price Forfeited/expired
Outstanding shares
Weighted Average Exercise Price Outstanding
Outstanding Aggregate Intrinsic Value
Outstanding shares Exercisable
Weighted Average Exercise Price Exercisable
Weighted-Average Remaining Contractual Term
Outstanding Exercisable Aggregate Intrinsic Value
Exercise price
Number Outstanding
Expiration date
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Outstanding shares
Weighted-Average Exercise Price,beginning
Weighted-Average Remaining Contractual Term, Outstanding
Aggregate Intrinsic Value
Issued
Weighted-Average Exercise Price Issued
Weighted-Average Remaining Contractual Term, Issued
Outstanding Aggregate Intrinsic Value, Grants
Forfeited/expired
Exercised
Weighted-Average Exercise Price Expired
Outstanding Aggregate Intrinsic Value, Exercised
Outstanding shares
Weighted-Average Exercise Price ending
Weighted-Average Remaining Contractual Term, Outstanding
Weighted-Average Remaining Contractual Term, Outstanding
Warrants Vested and expected to vest, Shares
Weighted-Average Exercise Price Vested and expected to vest
Weighted-Average Remaining Contractual Term Vested and expected to ves
Warrants Vested and expected to vest, Aggregate Intrinsic Value
Warrants Exercisable, Shares
Weighted-Average Exercise Price Exercisable
Weighted-Average Remaining Contractual Term Exercisable
Warrants Exercisable, Aggregate Intrinsic Value
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total restricted shares outstanding
Granted
Vested and issued
Forfeited
Total restricted shares outstanding
Vested restricted shares as of December 31, 2024
Vested restricted shares
Unvested restricted shares
Total
Subsidiary or Equity Method Investee, Sale of Stock [Table]
Subsidiary or Equity Method Investee [Line Items]
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, capital shares reserved for future issuance
Exercise price
Options vesting fair value
Restricted stock, unamortized
Weighted average period term
Warrants to purchase shares
Warrants outstanding exercise price
Shares issued for cashless exercise of warrants
Shares to be purchased
Stock price
Restricted common stock
Restricted common stock, value
Services, shares
Services, value
Share-based payment arrangement, noncash expense
Shares remaining
Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss
Average Non-Controlling interest percentage of profit/losses
Net loss attributable to non-controlling interest
Balance, January 1, 2025
Net income (loss) attributable to non-controlling interest
Balance, March 31, 2025
Majority interest
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Royalty percentage of net sales
Accounts payable due
Royalty payments
Commitment amount
Payments for royalties
Investor purchase of shares percentage description
Purchase of common stock up to the commitment amount
Investments
Advanced to the investor
Gain (Loss) from Litigation Settlement
Monthly consulting fee
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Revenues
Research and development
Research and development - stock-based compensation expenses
General and administrative - stock-based compensation expenses
Interest income (expense)
Gain on settlement and extinguishment of debt
Other income (expense)
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Other Liabilities, Current
Shares issued
Liability accrued
Number of shares granted
Number of shares granted value
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited
Series C 9% Convertible Preferred Stock [Member]
GainLossOnSettlementAndForgivenessOfAccountsPayable
Stock issued during period value sale of forgiveness of debt.
Stock issued during period value sale of common stock and warrants
Stock issued during period shares sale of common stock and warrants.
Stock issued during period shares sale of forgiveness of debt.
Accretion of deemed preferred stock dividend.
Deemed preferred stock dividend.
Common stock issued in settlement of debt.
Dividend payable on preferred stock charged to additional paid in capital.
Viral Clear[Member]
BioSig AI Sciences, Inc. [Member]
Working capital deficit.
One Customer [Member]
Two Customer [Member]
Three Customer [Member]
Prepaid Expenses [Policy Text Block]
ViralClear Pharmaceuticals, Inc. [Member]
BioSig AI Sciences, Inc. [Member]
Warrants Policy [Policy Text Block]
Right To Use Asset [TableText Block]
Operating lease right to use assets gross.
Operating lease right to use asset accumulated depreciation.
Lessor sales type lease discount rate.
Contract Assets Current [Member]
Contract Assets Noncurrent [Member]
Sales type lease invoiced to customer.
Accrued reimbursements current.
Accrued consulting current.
Accrued research and development expenses.
Accrued office expense and other expense.
Gain on settlement and forgiveness of debt
Promissory Note [Member]
Stock issued during period shares issued for forgiveness of accounts payable.
Stock issued during period value issued for forgiveness of accounts payable.
Purchase price of warrants.
Purchase Agreement [Member]
Class of warrant or rights granted.
Market Offering Agreement [Member]
2023 Long-Term Incentive Plan [Member]
Options Under 9.99 [Member]
Options 10.00 To 19.99 [Member]
Options 20.00 To 49.99 [Member]
Options 50.00 To 69.99 [Member]
Weighted average remaining contractual term options outstanding.
Schedule of Warrants or Rights Shares Authorized Exercise Price Range [Table Text Block]
Warrants At 0.3000 [Member]
Warrants expiration date description.
Warrants At 0.9547 [Member]
Warrants At 17800 [Member]
Warrants At 23875 [Member]
Warrants At 33640 [Member]
Warrants At 35730 [Member]
Warrants At 40660 [Member]
Warrants At 44550 [Member]
Warrants At 44660 [Member]
Warrants At 46626 [Member]
Warrants At 49252 [Member]
Warrants At 49290 [Member]
Warrants At 51358 [Member]
Warrants At 71810 [Member]
Warrants At 75020 [Member]
Warrants At 79630 [Member]
Warrants At 90000 [Member]
Warrants At 95960 [Member]
Warrants At 100992 [Member]
Warrants At 102600 [Member]
Warrants At 104678 [Member]
Warrants At 113000 [Member]
Warrants At 132800 [Member]
Warrants At 140000 [Member]
Warrants At 480000 [Member]
Warrants At 616000 [Member]
Shares issued for cashless exercise of warrants.
Class of warrants or right issued.
Class of warrantsr or right expried.
Class of warrant or right exercise price of warrants or rights issued.
Class of warrant or right exercise price of warrants or rights expired.
Class of warrant or rights weighted average exercise price of warrants or rights outstanding.
Warrants granted weighted average remaining contractual term.
Warrants weighted average remaining contractual term issued.
Warrants outstanding weighted average remaining contractual term.
Class of warrant or rights outstanding intrinsic value.
Class of warrant or rights vested and expected to vest outstanding.
Class of warrant or rights exercisable.
Class of warrant or rights weighted average exercise price of warrants or rights vested and expected to vest outstanding.
Class of warrant or rights weighted average exercise price of warrants or rights exercisable.
Warrants vested and expected to vest outstanding weighted average remaining contractual term.
Warrants exercisable weighted average remaining contractual term.
Class of warrant or rights vested and expected to vest outstanding intrinsic value.
Class of warrant or rights exercisable intrinsic value.
2019 Long-Term Incentive Plan [Member]
Range One [Member]
Range Two [Member]
Share based compensation arrangement by share based payment award equity instruments other than options vested number of shares.
Share based compensation arrangement by share based payment award equity instruments other than options unvested number of shares.
Share based compensation arrangement by share based payment award equity instruments other than options vested and unvested number of shares.
Schedule of NonControlling Interest [Table Text Block]
Net Income (Loss)
Average noncontrolling interest percentage of profit losses.
Subscription Agreement [Member]
Investor purchase of shares percentage description.
Purchase of common stock shares up to commitment amount.
Advanced to investor.
Payments for accrued.
Settlement Agreement [Member]
Research and development stock based compensation expenses.
General and administrative stock based compensation expenses.
Consultants [Member]
Endicott Management Partners LLC. [Member]
Streamex Exchange Corporation [Member]
Testing/Demo equipment [Member]
Proceeds from proceeds from sale of common stock under a at the market offerings net of issuance costs.
Customer One [Member]
Customer Two [Member]
Customer Three [Member]
Sales Agreement [Member]
Share based compensation arrangement by share based payment award options grants intrinsic value.
Key Consultant [Member]
Royalty percentage of net sales.
Twenty Twenty Seventeen Know How License Agreement [Member]
Tools Agreement [Member]
Viral Clear Patent Agreement [Member]
Trek Therapeutics [Member]
First Country [Member]
Second Country [Member]
Anthony Amato [Member]
Frederick D Hrkac [Member]
Mr Groenewald [Member]
Mr Amato [Member]
Class of warrants or right forfeited.
Stock issued during period value sale of extinguishment of debt.
Stock issued during period shares sale of extinguishment of debt.
Gain on settlement and extinguishment of accounts payable.
Gain on settlement and extinguishment of debt.
Interim Chief Financial Officer [Member]
Mr. Groenewald [Member]
Consultant [Member]
Research and development expenses.
BioSig AI Sciences, Inc. [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Net Income (Loss) Attributable to Parent
Dividends, Preferred Stock
Preferred Stock Dividends, Income Statement Impact
Net Income (Loss) Available to Common Stockholders, Basic
Shares, Outstanding
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings
Stock Issued During Period, Value, Other
Deemed preferred stock dividend
GainOnSettlementAndExtinguishmentOfAccountsPayable
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Leasing Receivables
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Receivables
Net Cash Provided by (Used in) Operating Activities
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Operating lease right to use asset accumulated depreciation
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss
Dividends Payable
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Class of warrant or rights outstanding intrinsic value
Class of warrants or right issued
ClassOfWarrantsOrRightForfeited
Class of warrant or rights weighted average exercise price of warrants or rights outstanding
Warrants outstanding weighted average remaining contractual term
Class of warrant or rights vested and expected to vest outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding
Class of warrant or rights exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnvestedNumberOfShares
ResearchAndDevelopmentExpenses
ResearchAndDevelopmentStockbasedCompensationExpenses